ACLARIS THERAPEUTICS INC's ticker is ACRS and the CUSIP is 00461U105. A total of 85 filers reported holding ACLARIS THERAPEUTICS INC in Q2 2019. The put-call ratio across all filers is - and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2019 | $8,723,000 | -75.3% | 3,983,025 | -32.4% | 0.31% | -76.9% |
| Q1 2019 | $35,302,000 | -18.9% | 5,893,416 | 0.0% | 1.35% | -22.3% |
| Q4 2018 | $43,552,000 | -3.0% | 5,893,416 | +90.5% | 1.74% | +8.3% |
| Q3 2018 | $44,916,000 | -18.1% | 3,093,416 | +12.7% | 1.61% | -16.5% |
| Q2 2018 | $54,832,000 | +14.0% | 2,745,705 | 0.0% | 1.93% | +15.5% |
| Q1 2018 | $48,105,000 | -12.7% | 2,745,705 | +22.9% | 1.67% | -23.1% |
| Q4 2017 | $55,076,000 | +35.2% | 2,233,416 | +41.5% | 2.17% | +18.1% |
| Q3 2017 | $40,726,000 | +300.5% | 1,577,927 | +320.8% | 1.84% | +238.6% |
| Q2 2017 | $10,170,000 | -9.1% | 375,000 | 0.0% | 0.54% | +25.8% |
| Q1 2017 | $11,183,000 | +9.9% | 375,000 | 0.0% | 0.43% | +2.9% |
| Q4 2016 | $10,178,000 | +242.6% | 375,000 | +223.3% | 0.42% | +203.6% |
| Q3 2016 | $2,971,000 | – | 116,000 | – | 0.14% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Foresite Capital Management V, LLC | 1,258,243 | $8,618,965 | 13.75% |
| Foresite Capital Management IV, LLC | 2,808,034 | $19,235,033 | 10.68% |
| Bain Capital Life Sciences Investors, LLC | 3,400,000 | $23,290,000 | 2.60% |
| GREAT POINT PARTNERS LLC | 1,691,768 | $11,588,611 | 2.11% |
| Samsara BioCapital, LLC | 696,171 | $4,768,771 | 1.46% |
| Altium Capital Management LP | 403,000 | $2,760,550 | 1.44% |
| BVF INC/IL | 7,064,736 | $48,393,442 | 1.30% |
| Aisling Capital Management LP | 434,455 | $2,976,017 | 1.23% |
| GREAT POINT PARTNERS LLC | 700,000 | $4,795,000 | 0.87% |
| VR Adviser, LLC | 1,040,754 | $7,129,165 | 0.75% |